Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A patient-derived CRISPR platform reveals selective dependencies in Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

ATAbderrahmane TagmountCVChris D. VulpeSPStanley Pounds

Discussion

Loading...

Member takes

Overview

CRISPR screening uncovers genetic vulnerabilities in primary AML cells, suggesting targeted therapies may improve clinical outcomes.

Key Points

  • This research aims to identify genetic dependencies and vulnerabilities in acute myeloid leukemia using CRISPR technology.
  • Conducted custom CRISPR/Cas9 screening targeting genes associated with AML and drug resistance.
  • Used mononuclear cells from peripheral blood or bone marrow of 9 AML patients.
  • Analyzed sgRNA abundance and conducted comparisons between adherent and suspension cell fractions.
  • Employed the MAGeCK algorithm for mapping genetic dependencies.
  • Identified distinct genetic dependencies in adherent AML cells linked to drug resistance.
  • Found that knocking out EDNRA inhibits AML cell growth, indicating it as a potential therapeutic target.
  • Characterized SOD1 as linked to poor outcomes in AML and potential for synthetic lethality.
  • Noted higher expression of TRAPPC9, SUZ12, and ERG in primary AML cells compared to normal controls.

Cite This Study

Tagmount et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da3ahttps://doi.org/10.1182/blood-2025-3504
View Full Paper
Ask AI
Bookmark
Share